Time to first relapse as an endpoint in multiple sclerosis clinical trials

Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing multiple sclerosis: A systematic review and meta-analysis

(2012) Richard Nicholas et al.   Multiple Sclerosis Journal

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial

(2011) Giancarlo Comi et al.   LANCET NEUROLOGY

A parametric model fitting time to first event for overdispersed data: application to time to relapse in multiple sclerosis

(2011) Paola Siri et al.   LIFETIME DATA ANALYSIS

Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis

(2011) M. P. Sormani et al.   NEUROLOGY

The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability

(2010) Antonio Scalfari et al.   BRAIN

Assessing changes in relapse rates in multiple sclerosis

(2010) Seidu Inusah et al.   Multiple Sclerosis Journal

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

(2010) Gavin Giovannoni et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Statistical methods for the analysis of relapse data in MS clinical trials

(2009) Y.C. Wang et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

(2009) G Comi et al.   LANCET

Ethics of placebo-controlled clinical trials in multiple sclerosis: A reassessment

(2008) C. H. Polman et al.   NEUROLOGY